Skip to content
- Leveraging Mycobacterium tuberculosis Rv1507A Protein for Improved Immunogenicity in Mycobacterium bovis BCG Vaccine. Naqvi N, Alam A, Shariq M, Ahuja Y, Mitra DK, Hasnain SE, Ehtesham NZ. Immunology. 2026 Mar;177(3):526-539. doi: 10.1111/imm.70063. Epub 2025 Nov 8.
- Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials. Seshadri C, Flynn JL, Maiello P, Schnappinger D, Wilkinson RJ, Gordon SB, Mwandumba HC, Jambo KC, Hoft DF, Rubin EJ, Jamrozik E, Fortune SM, Kublin JG. Lancet Microbe. 2026 Mar;7(3):101278. doi: 10.1016/j.lanmic.2025.101278. Epub 2026 Jan 23. PMID: 41587559.
- Synthesis of an Adjuvant-Free Single Polypeptide-Based Tuberculosis Subunit Vaccine that Elicits In Vivo Immunogenicity in Rats. Phogat S, Yadav J, Chaudhary D, Jaiwal R, Jaiwal PK. Mol Biotechnol. 2026 Mar;68(3):1194-1213. doi: 10.1007/s12033-025-01431-7. Epub 2025 Apr 2.
- Toward tuberculosis elimination: an update on tuberculosis vaccines in clinical trials. Martín C, Gonzalo-Asensio J, Aguiló N, Arbués A. Int J Infect Dis. 2026 Mar 1:108513. doi: 10.1016/j.ijid.2026.108513. Epub ahead of print.
- Potential of Vγ9Vδ2T cells in tuberculosis: integration of innate and adaptive immunity for vaccine development. Di D, Gao C, Deng Y, Li Y, Zhang Y. PeerJ. 2026 Mar 4;14:e20904. doi: 10.7717/peerj.20904.
- Broad innate immune activation enhances the protective efficacy of rBCG-LTAK63 against Mycobacterium tuberculosis. Carvalho ACO, Trentini MM, Rodriguez D, Marques-Neto LM, Silveira PHS, Starobinas N, Oliveira SC, Leite LCC, Kanno AI. Front Immunol. 2026 Mar 4;17:1758476. doi: 10.3389/fimmu.2026.1758476.
- Immunoinformatic Design and Evaluation of a Multi-Epitope mRNA Vaccine RP14914P Targeting Latent Tuberculosis Infection. Tian Y, Zhang M, Ali SL, Abduldayeva A, Zhou S, An Y, Li Y, Ni R, Zhang L, Liu Y, Sun W, Gong W. 2026 Mar 9;15(3):297. doi: 10.3390/pathogens15030297.
- An Rv1471-expressing chimpanzee adenovirus vaccine confers protection against tuberculosis by inducing alveolar macrophage trained immunity and polyfunctional T-cell responses. Wang H, Zhang Y, Li J, Wu J, Huang S, Xie S, Huang X, Wang J, Fan XY, Hu Z. Emerg Microbes Infect. 2026 Mar 10;15(1):2637292. doi: 10.1080/22221751.2026.2637292. Epub ahead of print.
- Editorial: Vaccines and molecular therapeutics for tuberculosis. Sable SB, Velu V, Kupz A. Front Immunol. 2026 Mar 10;17:1809428. doi: 10.3389/fimmu.2026.1809428.
- Mycobacterium tuberculosisantigen-containing exosomes reinforce BCG vaccine efficacy by augmenting long-term protection and memory response against experimental tuberculosis in BALB-C mice. Sharma M, Afghan S, Singh A, Alam I, Agarwal M, Shahid M, Atif SM, Khan S, Malik SS, Yenuganti VR, Ansari MA. Front Immunol. 2026 Mar 13;17:1742207. doi: 10.3389/fimmu.2026.1742207.
- Anticipating tuberculosis vaccine acceptability in Kenya and South Africa: a narrative review of behavioral and social drivers and strategies to optimize acceptability. Giovanatti A, Shapiro AE. Vaccine. 2026 Mar 13;79:128457. doi: 10.1016/j.vaccine.2026.128457. Epub ahead of print.
- A novel mi3 VLP nanoparticle vaccine displaying ESAT-6 -PPE57 -PPE68 -EsxV antigens exhibits superior immunogenicity and Mycobacterium tuberculosis growth inhibition. Chen Q, Huang N, Liao M, Zhang X, Aiman S, Li S, Chen M, Wang J, Ouyang P, Zhang Y, Zhu J, Huang K, Xu G. Int Immunopharmacol. 2026 Mar 15;173:116264. doi: 10.1016/j.intimp.2026.116264. Epub 2026 Feb 1.
- AXIN1-Dependent Regulation of Lung Macrophage MHC II Expression Shapes CD4⁺ T Cell Responses during BCG Infection. Liang X, Chen R, Zeng Y, Peng H, Feng Z, Zhou H, Kong X, Qin J, Zhu L, Li G, Song H, Li Y, Wang Y. Biochem Cell Biol. 2026 Mar 16. doi: 10.1139/bcb-2025-0382. Epub ahead of print.
- Accelerating research and development of new vaccines against tuberculosis: 5-year progress on the global roadmap. van Riet E, Corleis B, Giersing BK, Hatherill M, Burhan E, Jassat W, White RG, Lewinsohn D, Cobelens F. Lancet Infect Dis. 2026 Mar 18:S1473-3099(26)00019-8. doi: 10.1016/S1473-3099(26)00019-8. Epub ahead of print. PMID: 41864213.
- Acceptability of a proposed new tuberculosis vaccine among people deprived of liberty in Brazil. Bampi JVB, Arcanjo GGA, Santos KM, Ventura MS, Lemos EF, Clark RA, Thomas KA, White RG, Croda J. 2026 Mar 18;79:128492. doi: 10.1016/j.vaccine.2026.128492. Epub ahead of print.
- A point-mutated Ag85B antigen improves recombinant bacterial expression and protects mice from aerosol tuberculosis challenge. Hsu WL, Jiao Y, Hvasta M, Tran KN, Troyer BT, Huang WC, Kuhlman B, Obregon-Henao A, Lovell JF. Vaccine. 2026 Mar 19;76:128281. doi: 10.1016/j.vaccine.2026.128281. Epub 2026 Feb 2.
- Exploring the ethics of tuberculosis human challenge models. Rohrig A, Morrison J, Kleinwaks G, Pugh J, McShane H, Savulescu J. J Med Ethics. 2026 Mar 20;52(4):251-260. doi: 10.1136/jme-2023-109234.
- Rare variable tuberculosis antigens induce predominant Th17 responses in human infection. Ogongo P, Wassie L, Tran A, Columbus D, Huffaker J, Sharling L, Ouma G, Ouma SG, Bobosha K, Lindestam Arlehamn CS, Gandhi NR, Auld SC, Rengarajan J, Day CL, Queiroz A, Araújo-Pereira M, Fukutani E, Andrade BB, Altman JD, Blumberg HM, Ernst JD; TBRU ASTRa Study Group. JCI Insight. 2026 Jan 27;11(6):e202134. doi: 10.1172/jci.insight.202134.
- CD8+T cells sustain vaccination-induced immunity against dissemination of contained tuberculosis in immunosuppressed hosts. Miranda-Hernandez S, Kumar M, Henderson A, Graham E, Tan X, Taylor J, Meehan MT, Ceja Z, Del Pozo-Ramos L, Pan Y, Tsui E, Donovan ML, Rentería ME, Flores-Valdez MA, Blumenthal A, Nguyen Q, Subbian S, Field MA, Kupz A. Nat Commun. 2026 Mar 24. doi: 10.1038/s41467-026-70911-4. Epub ahead of print.
- Peptide nanofibers and PAMP agonist combinations enhance pulmonary CD4+T cell functionality of immune recall to vaccination. Files MA, Das A, Kim D, Buck J, Endsley JJ, Rudra JS. J Nanobiotechnology. 2026 Mar 25. doi: 10.1186/s12951-026-04305-5. Epub ahead of print.
